Efficacy and Safety of Dabigatran Compared to Warfarin in Patients With Paroxysmal, Persistent, and Permanent Atrial Fibrillation
作者： Greg Flaker , Michael Ezekowitz , Salim Yusuf , Lars Wallentin , Herbert Noack
DOI: 10.1016/J.JACC.2011.10.896
关键词:
摘要: To the Editor: Dabigatran etexilate 150 mg twice daily (bid) is more effective than warfarin for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF) no increase major bleeding ([1][1]). Dabigatran 110 bid reduces compared to
elsevier.com
onlinejacc.org 参考文章(2)
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation The New England Journal of Medicine. ,vol. 360, pp. 2066- 2078 ,(2009) , 10.1056/NEJMOA0901301
Stuart J Connolly, Michael D Ezekowitz, Salim Yusuf, John Eikelboom, Jonas Oldgren, Amit Parekh, Janice Pogue, Paul A Reilly, Ellison Themeles, Jeanne Varrone, Susan Wang, Marco Alings, Denis Xavier, Jun Zhu, Rafael Diaz, Basil S Lewis, Harald Darius, Hans-Christoph Diener, Campbell D Joyner, Lars Wallentin, RE-LY Steering Committee and Investigators, None, Dabigatran versus Warfarin in Patients with Atrial Fibrillation New England Journal of Medicine. ,vol. 361, pp. 1139- 1151 ,(2009) , 10.1056/NEJMOA0905561